--- title: "Biomea Fusion | 8-K: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/285996849.md" datetime: "2026-05-11T21:01:12.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285996849.md) - [en](https://longbridge.com/en/news/285996849.md) - [zh-HK](https://longbridge.com/zh-HK/news/285996849.md) generator: "portal-rs" --- # Biomea Fusion | 8-K: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.17. EBIT: As of FY2026 Q1, the actual value is USD -12.77 M. #### Cash, Cash Equivalents, and Restricted Cash Biomea Fusion, Inc. reported cash, cash equivalents, and restricted cash of $45,062 thousand as of March 31, 2026, which is a decrease from $56,181 thousand as of December 31, 2025. #### Net Loss The net loss attributable to common stockholders for Biomea Fusion, Inc. was - $12.4 million for the three months ended March 31, 2026, including $1.6 million of stock-based compensation, compared to - $29.3 million for the same period in 2025, which included $3.2 million of stock-based compensation. The net and comprehensive loss was - $12,415 thousand for the three months ended March 31, 2026, compared to - $29,262 thousand for the same period in 2025. #### Research and Development (R&D) Expenses R&D expenses for Biomea Fusion, Inc. were $9,120 thousand for the three months ended March 31, 2026, marking a decrease of $13,777 thousand from $22,897 thousand for the same period in 2025. This reduction was primarily due to a $7.6 million decrease in external costs, a $4.5 million decrease in personnel-related expenses, and a $1.7 million decrease in facilities and other allocated expenses. #### General and Administrative (G&A) Expenses G&A expenses for Biomea Fusion, Inc. were $3,654 thousand for the three months ended March 31, 2026, a decrease of $3,161 thousand from $6,815 thousand for the same period in 2025. This decrease was mainly driven by a $1.9 million reduction in personnel-related expenses, a $1.1 million decrease in corporate-related expenses, and a $0.2 million decrease in facilities and other allocated expenses. #### Total Operating Expenses Total operating expenses were $12,774 thousand for the three months ended March 31, 2026, compared to $29,712 thousand for the same period in 2025. #### Loss from Operations Loss from operations was - $12,774 thousand for the three months ended March 31, 2026, compared to - $29,712 thousand for the same period in 2025. #### Change in Fair Value of Common Warrant Liability Biomea Fusion, Inc. reported a change in fair value of common warrant liability of - $581 thousand for the three months ended March 31, 2026, compared to $0 thousand for the same period in 2025. #### Gain on Sale of Property and Equipment Biomea Fusion, Inc. reported a gain on sale of property and equipment of $510 thousand for the three months ended March 31, 2026, compared to $0 thousand for the same period in 2025. #### Interest and Other Income, Net Interest and other income, net, was $430 thousand for the three months ended March 31, 2026, compared to $450 thousand for the same period in 2025. #### Stock-Based Compensation Expense Total stock-based compensation expense was $1,582 thousand for the three months ended March 31, 2026, compared to $3,169 thousand for the same period in 2025. This included $784 thousand for R&D and $798 thousand for G&A in 2026, compared to $1,920 thousand for R&D and $1,249 thousand for G&A in 2025. #### Working Capital Working capital for Biomea Fusion, Inc. was $36,655 thousand as of March 31, 2026, compared to $46,949 thousand as of December 31, 2025. #### Total Assets Total assets for Biomea Fusion, Inc. were $46,385 thousand as of March 31, 2026, compared to $58,572 thousand as of December 31, 2025. #### Stockholders’ Equity Stockholders’ equity for Biomea Fusion, Inc. was $18,719 thousand as of March 31, 2026, compared to $29,552 thousand as of December 31, 2025. #### Outlook / Guidance Biomea Fusion, Inc. projects its cash runway to extend into the first quarter of 2027. The company expects topline 26-week data from its Phase II COVALENT-211 and COVALENT-212 clinical trials in the fourth quarter of 2026, and initial 28-day weight reduction data from the Phase I GLP-131 clinical trial in the second quarter of 2026. Additionally, a Phase II trial for recently diagnosed Type 1 Diabetes patients is planned for initiation in the second half of the year. ### Related Stocks - [BMEA.US](https://longbridge.com/en/quote/BMEA.US.md) ## Related News & Research - [JILL: Q2 FY26 delivered higher net income and margins, aided by a $13.3M tariff refund and raised FY26 outlook](https://longbridge.com/en/news/298443175.md) - [HPS/PayMedix Named a 2026 Best and Brightest Company to Work For](https://longbridge.com/en/news/298358823.md) - [Annaly Capital declares Q3 2026 dividend of $0.75 per share](https://longbridge.com/en/news/298499808.md) - [Vivos Therapeutics amends 8-K to correct report date to Sept. 2, 2026](https://longbridge.com/en/news/298368513.md) - [Acteos delays H1 2026 results release to Oct. 28](https://longbridge.com/en/news/298618428.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**